Sempervirine inhibits RNA polymerase I transcription independently from p53 in tumor cells
Open Access
- 28 October 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Cell Death Discovery
- Vol. 6 (1), 1-15
- https://doi.org/10.1038/s41420-020-00345-4
Abstract
In the search of small molecules that can target MDM2/p53 pathway in testicular germ cell tumors (TGCTs), we identified sempervirine (2,3,4,13-tetrahydro-1H-benz[g]indolo[2,3-a]quinolizin-6-ium), an alkaloid of Gelsemium sempervirens, that has been previously proposed as an inhibitor of MDM2 that targets p53-wildtype (wt) tumor cells. We found that sempervirine not only affects cell growth of p53-wt cancer cells, but it is also active in p53-mutated and p53-null cells by triggering p53-dependent and independent pathways without affecting non-transformed cells. To understand which mechanism/s could be activated both in p53-wt and -null cells, we found that sempervirine induced nucleolar remodeling and nucleolar stress by reducing protein stability of RPA194, the catalytic subunit of RNA polymerase I, that led to rRNA synthesis inhibition and to MDM2 block. As shown for other cancer cell models, MDM2 inhibition by nucleolar stress downregulated E2F1 protein levels both in p53-wt and p53-null TGCT cells with the concomitant upregulation of unphosphorylated pRb. Finally, we show that sempervirine is able to enter the nucleus and accumulates within the nucleolus where it binds rRNA without causing DNA damage. Our results identify semperivirine as a novel rRNA synthesis inhibitor and indicate this drug as a non-genotoxic anticancer small molecule.Keywords
Funding Information
- Ministero dell'Istruzione, dell'Università e della Ricerca (2017ATZ2YK_002, 2010M4NEFY_004)
- Ministero dell'Istruzione, dell'Università e della Ricerca
This publication has 48 references indexed in Scilit:
- Reduced Proficiency in Homologous Recombination Underlies the High Sensitivity of Embryonal Carcinoma Testicular Germ Cell Tumors to Cisplatin and Poly (ADP-Ribose) Polymerase InhibitionPLOS ONE, 2012
- MDM2 antagonist Nutlin-3a potentiates antitumour activity of cytotoxic drugs in sarcoma cell linesBMC Cancer, 2011
- Preclinical and clinical activity of sunitinib in patients with cisplatin-refractory or multiply relapsed germ cell tumors: a Canadian Urologic Oncology Group/German Testicular Cancer Study Group cooperative studyAnnals of Oncology, 2011
- Opposing effects of retinoic acid and FGF9 onNanos2expression and meiotic entry of mouse germ cellsJournal of Cell Science, 2010
- Structure-based Design of High Affinity Peptides Inhibiting the Interaction of p53 with MDM2 and MDMXOnline Journal of Public Health Informatics, 2010
- Microsatellite Instability, Mismatch Repair Deficiency, and BRAF Mutation in Treatment-Resistant Germ Cell TumorsJournal of Clinical Oncology, 2009
- Targeting Mdm2 and Mdmx in Cancer Therapy: Better Living through Medicinal Chemistry?Molecular Cancer Research, 2009
- Subcellular localization and regulation of type-1C and type-5 phosphodiesterasesBiochemical and Biophysical Research Communications, 2006
- Novel MDM2 p53‐Independent Functions Identified through RNA Silencing TechnologiesAnnals of the New York Academy of Sciences, 2005
- Human male germ cell tumor resistance to cisplatin is linked to TP53 gene mutationOncogene, 1998